Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.
Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.
The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.
The interleukin-1 receptor inhibitor anakinra merits further investigation for the treatment of Kawasaki disease, suggest findings from a phase IIa trial presented at the EULAR 2019 congress in Madrid, Spain.
Phase III study findings reported at the EULAR 2019 congress in Madrid, Spain, provide support for the use of tanezumab, a monoclonal antibody against nerve growth factor, to improve pain and physical function among individuals with osteoarthritis.
Patients with early moderate-to-severe rheumatoid arthritis who test positive for HLA-DRB1 shared epitope alleles may benefit more from abatacept than adalimumab, an analysis of head-to-head data indicates.
Most patients with rheumatoid arthritis who achieve low disease activity with the Janus kinase inhibitor tofacitinib plus methotrexate can withdraw methotrexate without significant worsening of disease activity, findings from the ORAL Shift trial show.
Filgotinib, given in combination with methotrexate, may be a promising treatment option for methotrexate-naïve patients with moderate-to-severe rheumatoid arthritis, indicate findings from the FINCH 3 trial.
Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.
Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.
Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.
Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.
Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.
Rheumatoid arthritis patients who achieve low disease activity with tocilizumab and low-dose glucocorticoids should be considered for glucocorticoid tapering, suggests research presented at the EULAR 2019 congress in Madrid, Spain.